Neurocrine Biosciences, Inc. (NBIX)
| Previous close | 111.62 |
| Open | 111.69 |
| Bid | 111.77 x 100 |
| Ask | 112.06 x 100 |
| Day's range | 111.14 - 112.55 |
| 52-week range | 103.63 - 157.98 |
| Volume | |
| Avg. volume | 916,670 |
| Market cap | 11.32B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 33.77 |
| EPS (TTM) | 3.32 |
| Earnings date | 30 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 167.79 |
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 30, 2024.
Simply Wall St.Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices...
- PR Newswire
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules for the long-term treatment of adults with chorea associated with Huntington's disease. Robust and sustained improvements in chorea associated with Huntington's disease were observed through Week 104 in patients, irrespective of concomitant antipsychotic therapy use. These results (Poster #1465) will be presented on September 30 during the
